Full Press Release Details
GAITHERSBURG, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2020 financial results and operational highlights following the close of U.S. financial markets on Monday, March 1, 2021.
| Conference call details are as follows: | |
| Date:Time:Dial-in number:Passcode:Webcast: | March 1, 20214:30 p.m. U.S. Eastern Time (ET)(877) 212-6076 (Domestic) or (707) 287-9331 (International)3797013www.novavax.com/events |
| Conference call and webcast replay: | |
| Date:Dial-in number:Passcode:Webcast: | Starting at 7:30 p.m. ET, March 1, 2021(855) 859-2056 (Domestic) or (404) 537-3406 (International)3797013www.novavax.com/events, until June 1, 2021 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visitwww.novavax.comand connect with us onTwitterandLinkedIn.